Sanofi SA(0O59)
EUR --+0.00%
Reward57Moderate
Risk12Low
📊50%Data
Strong 16% profit margin
0O59
+0.0 · +0.00%
EUR · LSE
Sanofi SA |
Quality Compounder
Market Cap:117.64Bn
ℹ️
Reward Rating
57
Moderate
Top 50% (model universe)
50% data coverage
ℹ️
Risk Rating
12
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on 0O59 to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Sanofi SA?

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions.

0O59 · Verdict

Solid reward · low risk

0O59 scores well on cash flow and volatility with no major weaknesses flagged in the model.

Based on 75% data coverage

0O59 · Verdict

What’s working & what to watch

Strengths 3

  • Cash flow95/100

    Top decile vs peers

  • Volatility95/100

    Top decile vs peers

  • Balance sheet80/100

    Current ratio 1.42

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Sanofi SA?

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. The company is listed on the LSE in UK, with a market capitalisation of 117.64B.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (57)

The scoring profile indicates moderate reward potential, with valuation and profitability as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorN/A
Market Cap117.64B
P/E RatioN/A
Dividend YieldN/A
52 Week High94.2036
52 Week Low70.9227
Last AnnualDecember
IPO DateN/A
IncorporatedUK
Shares OutstandingN/A
No. of Employees74,846
IndustryN/A
ExchangeLSE
Beta0.319
CurrencyEUR